• Researcher Profile

    Peter Hammerman, MD, PhD

     
    Peter Hammerman, MD, PhD

     
    Assistant Professor of Medicine, Harvard Medical School

    Center/Program

    Thoracic Oncology

    Office phone: 617-632-6049
    Fax: 617-632-5786

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology

    Interests

    Squamous cell lung cancer, Novel lung cancer therapeutics


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Select Publications

    • Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T, Thompson CB. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res. 2004 Nov 15;64(22):8341-8.
    • Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005 Nov;5(11):844-52.
    • Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood. 2005 Jun 1;105(11):4477-83. Epub 2005 Feb 10. PMCID:PMC1895036.
    • Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med. 2005 Jan 17;201(2):259-66. Epub 2005 Jan 10. PMCID: PMC2212793
    • Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ, Hilbert DM, Thompson CB. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood. 2008 Jan 15;111(2):750-60. Epub 2007 Oct 17. PMCID: PMC2200845
    • Hammerman PS, Janne PA, Johnson BE. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Clin Cancer Res. 2009 Dec 15;15(24_:7502-7509.
    • Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant. 2009 Nov;15(11):1447-54. Epub 2009 Sep 1.
    • Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high risk patients with diffuse large B-cell lymphoma. Cancer. 2010 Sep 15;116(18):4283-90.
    • Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka K, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351. Epub 2011 Jun 7.
    • Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng Z, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Solterman A, Moch H, Koker M, Leenders F, Fabler F, Querings S, Ansen S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson MM. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. 2011. Epub 2011 April 3.
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now